After chemotherapy for the treatment of metastatic bladder urothelial carcinoma (UC), most
patients inevitably encounter drug resistance and resultant treatment failure …

Cisplatin-based chemotherapy is the standard treatment for bladder urothelial carcinoma
(UC). Most patients experience chemoresistance, the primary cause of treatment failure …

Urothelial carcinoma (UC) comprises the majority of bladder cancers. Standard platinum-
based chemotherapy has a response rate of approximately 50%, but drug resistance …

Background: The inhibition of ubiquitin-specific proteases (USPs) is a novel and promising
direction in the development of molecularly targeted therapies in oncology. The aim of the …

Background/Aim: Activation of the ubiquitin-proteasome system (UPS) has been shown to
be associated with drug resistance in cancer. Using bladder cancer cells, we investigated …

ABT‑737 is a recently reported inhibitor of members of the Bcl‑2 family of apoptosis
regulators. However, to the best of our knowledge, its necroptosis‑inducing function in …

Cis‑diamine‑dichloroplatinum II (cisplatin, CDDP) is a key chemotherapeutic regimen in the
treatment of oral squamous cell carcinoma (OSCC). However, the therapeutic efficacy of …

The post-translational modification of proteins by ubiquitinating enzymes plays a central role
in a number of cellular functions, such as cell proteolysis, DNA repair, and cell signaling and …

In advanced bladder cancer, cisplatin-based chemotherapy has been the standard
treatment for many years, but there are many problems in terms of side-effects. Recently, a …

Aims: The purpose of our study was to explore the combination effect of epirubicin and
Bacillus Calmette Guerin (BCG) and its mechanism. Background: Bladder cancer is a threat …